Dec. 4 at 4:21 PM
$TXMD 
Cosette Pharma, backed by Arista and Hamilton Lane, clearly needs an exit ramp if you look at their longstanding investment in Cosette. Their path to public markets has been messy, but one thing is clear: they aren’t doing all this maneuvering for fun. There’s an endgame.
On the other side, you’ve got Rubric Capital—TXMD’s parent with a history of pulling deep value plays. They’re sitting on a shell with cash flow potential and 640M shares ready to be authorized post Dec. 15th shareholder meeting.
Meanwhile, Mayne has been the regulatory thorn in everyone’s side, nearly derailing the cleanest merger route. But with the FIRB blocking that deal, Cosette + TXMD can keep moving forward without waiting on Mayne to figure it out.
👀I think we’re 30-60 days out from fireworks.
